We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

FDA Harvests Data Using IO Informatics’ Sentient Software

FDA Harvests Data Using IO Informatics’ Sentient Software

FDA Harvests Data Using IO Informatics’ Sentient Software

FDA Harvests Data Using IO Informatics’ Sentient Software

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "FDA Harvests Data Using IO Informatics’ Sentient Software"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IO Informatics, Inc. announces an agreement to license its Sentient Suite of Life Science & Healthcare software to the FDA Center for Veterinary Medicine.

“We are pleased to have the Sentient system deployed at the FDA,” stated Robert Stanley, President and CEO of IO Informatics. “Sentient is a powerful data integration and knowledge building suite that will make it possible for the FDA to conduct reliable toxicity assessment in less time and for lower cost, specifically by enabling them to move more effectively from animal studies to cell cultures – reducing the number of live animals required to produce meaningful knowledge. Among the advantages they have identified are the ease of implementing Sentient to pull in data from a variety of sources and formats, as well as its accessibility and ease of use for researchers and managers. These capabilities will allow them to quickly get a better handle on projects and make it easier to achieve success in research.”

At the FDA, Sentient will allow researchers to acquire, digest and access data from genomics (RNA, µRNA), and proteomics (serum proteome: abundance & activity) in multiple tissues (blood, liver, kidney).

In addition, through the use of the Sentient framework, scientists will be able to conduct tissue analytics from biopsies (liver, kidney) more efficiently and accurately and will be provided with animal genotyping for response correlation.

Via the Sentient suite of software, researchers will share and access experimental data from microarrays (genomics), 2DE gels (proteomics), mass spectrometry, microscopy (tissue images), pK assays (blood chemistry) and combined genetic/phenotypic/visual animal classification.

The Sentient environment is used to identify and qualify multi-modal, cross-species-specific toxicity biomarkers. This provides an intimate understanding of biological systems and ‘connects the dots’ for toxicity responses common to animal and tissue cultures, despite the involvement of many incomparable pathways.

As a result, the Veterinary Center researchers will be able to confidently determine toxicity with easier to handle cell cultures, at a much faster turnover (as the reproductive cycle is extremely short; long-term effects can be studied effectively). Using these methods, many different experimental layouts can be pursued in parallel and at significantly lower operating costs, due to the decrease in the live animal facilities needed.